GLP-1 Therapies Research,
what lands in your inbox each week:
- 📚7 fresh studies
- 📝plain-language summaries
- ✅direct links to original studies
- 🏅top journal indicators
- 📅weekly delivery
- 🧘♂️always free
some of our latest newsletters:
(select one to read it below)
Semaglutide linked to 2.5x higher risk of sudden vision loss
New research on GLP-1 drugs like semaglutide and tirzepatide reveals both promising benefits and unexpected risks across multiple health conditions.
🚨 Vision Loss Risk Emerges with Popular Weight Loss Drug
Meta-analysis of 1.6 million patients found semaglutide users had 2.52 times higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) - sudden vision loss from blocked blood flow to the optic nerve
Risk was particularly high in diabetic patients (2.41x increased risk) with 118 cases per 100,000 semaglutide users annually
Five studies consistently showed this association, with 99.9% probability that the increased risk is real
Why it matters: NAION causes permanent vision loss and was previously considered rare, but this analysis suggests it may be an underrecognized side effect of the world's most popular weight loss medication.
Key Findings
🧠 Depression Motivation Gets Boost from Semaglutide
72 people with major depression showed increased willingness to exert physical effort for rewards after 16 weeks of semaglutide treatment
The drug reduced "effort discounting" - making physical tasks feel less burdensome relative to potential rewards
Participants were more likely to choose difficult tasks when the expected payoff was higher
📊 Weight Loss Plateau Explained by Energy Math
Mathematical modeling showed semaglutide-induced weight loss peaks at 24% after 96 weeks, then plateaus for 78 weeks despite continued treatment
Energy intake initially dropped 32% in first 4 weeks but gradually rose to match energy expenditure by week 98
After stopping treatment, energy intake exceeded baseline levels, causing 5.3% weight regain
💊 Tirzepatide Shows Promise for Multiple Health Conditions
Meta-analysis of 25,847 patients found tirzepatide reduced heart failure events by 38% and resolved fatty liver disease in 62% of patients
Also linked to 21.9 fewer sleep apnea episodes per hour and 5.8 mmHg blood pressure reduction
Comprehensive analysis across 10 health domains showed benefits beyond diabetes and obesity
🔬 Quintuple-Action Drug Outperforms Current Treatments
Scientists developed a single molecule combining GLP-1, GIP, and three PPAR receptor targets in mouse studies
This "quintuple agonist" reduced body weight and blood sugar more effectively than current GLP-1 drugs
Works by delivering anti-inflammatory effects directly to cells that express incretin receptors
🏥 Real-World Cancer Patient Protection Observed
GLP-1 drugs were linked to reduced heart damage in cancer patients receiving cardiotoxic treatments
Benefits were strongest in women, younger patients, and those with obesity or type 2 diabetes
Effects were particularly pronounced with anthracycline chemotherapy, a known heart-damaging treatment
🧬 Genetics May Predict Drug Response and Side Effects
Two independent genetic variants near the GLP-1 receptor gene affect BMI through different pathways
One variant (rs12213929) influences diabetes risk independently of weight, while another (rs13216992) works primarily through body weight
People with 4 risk alleles had 0.47 kg/m² higher BMI than those with none
Implications
While GLP-1 drugs continue showing benefits across multiple health conditions - from depression to cancer protection - the emerging vision loss risk highlights the need for careful monitoring. The combination of genetic insights and mathematical modeling suggests we're moving toward more personalized approaches to these powerful medications.
Science is the only real news.
The rest is just drama 📰
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli 🧠🥦
And look, it's not that science never makes the news.
But think about when it does—does the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerd… 🔭🤖
…with a superpower…
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves 🥦
The real-time unfolding of science is too interesting not to follow.